Teva’s Re-Rating Still Has Room To Run (NYSE:TEVA)
· seekingalpha.com
Teva (TEVA) shifts toward specialty drugs, targets higher margins and lower leverage through 2027. Click here to read my most recent analysis.
Teva Pharmaceutical’s ( TEVA ) story is really about the transformation taking place across the business. Over the past year, the stock has gained 126%. My mo...